ContraFect

ContraFect EBITDA CAGR 5Y

EBITDA CAGR (5 Year) of ContraFect (CFRXQ) as of Oct 19, 2026.

EBITDA CAGR 5Y

-

Last updated:

EBITDA CAGR (5 Year) of ContraFect is 2026 - . EBITDA CAGR (5 Year) of ContraFect was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

On Eulerpool you can find the complete historical development of EBITDA CAGR (5 Year) ContraFect since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBITDA CAGR shows the compound annual growth rate of EBITDA over five years.

To evaluate EBITDA CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA CAGR (5 Year).

EBITDA CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA CAGR (5 Year)'s ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ContraFect

All Key Metrics — ContraFect